Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor dose-escalation in relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma
jRCT2080223979Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), sponsored by Ono Pharmaceutical. Started Jul 2018; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2080223979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223979.